Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence
- 188 Downloads
Men who have sex with men require special attention for human papillomavirus vaccination given elevated infection risks and the development of, in particular, anal cancer.
Our purpose was to review the cost effectiveness of human papillomavirus vaccination for both currently vaccine-eligible and non-eligible individuals, particularly the men-who-have-sex-with-men population, and synthesize the available evidence.
We systematically searched for published articles in two main databases (PubMed and EMBASE). Screening and data extraction were performed by two independent reviewers. The risk of bias was assessed using a validated instrument (Bias in Economic Evaluation, ECOBIAS). Methodological aspects, study results, and sensitivity analyses were extracted and synthesized to generate a consistent overview of the cost effectiveness of human papillomavirus vaccination in the men-who-have-sex-with-men population.
From 770 identified articles, four met the inclusion criteria. Across the studies, human papillomavirus vaccination showed incremental cost-effectiveness ratios ranging from dominant to US$96,146 and US$14,000 to US$18,200 for tertiary prevention and primary prevention, respectively. The incremental cost-effectiveness ratio seemed most sensitive to vaccine efficacy, vaccine costs, and the incidence of anal cancer in the selected target populations.
This review presents the human papillomavirus vaccine, both as a primary and adjuvant (tertiary) vaccination, as a potentially cost-effective strategy for preventing mainly—but not limited to only—anal cancer in men-who-have-sex-with-men populations.
DS, AW, and MJP developed the research question and methodology, DS and AW performed the search term development, screening, and data extraction, and conducted the analysis. All authors contributed to the manuscript.
Compliance with Ethical Standards
These findings are the result of work supported by the University of Groningen and Directorate General of Higher Education (DIKTI) Scholarship, Ministry of National Education, Indonesia. The views expressed in this study are solely those of the authors and no official endorsement by both institutions is intended or inferred.
Conflict of interest
Didik Setiawan, Abrham Wondimu, KohJun Ong, Albert Jan van Hoek, and Maarten J. Postma received no financial compensation for their contributions to this work; however, Maarten J. Postma received grants and honoraria from various pharmaceutical companies, including those developing, producing, and marketing human papillomavirus vaccines.
Data availability statement
The data, particularly the included articles, that mainly support the findings of this review are publicly available.
- 2.Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.PubMedPubMedCentralCrossRefGoogle Scholar
- 4.Gao G, Smith DI. Human papillomavirus and the development of different cancers. Cytogenet Genome Res. 2017;150(3–4):185–93.Google Scholar
- 6.International Agency for Research on Cancer. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, vol 90. 2007. p. 468–71. http://monographs.iarc.fr/ENG/Monographs/vol90/mono90-6.pdf%5Cnhttp://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf. Accessed 8 Feb 2018.
- 7.Giuliano AR, Nyitray AG, Kreimer ARAR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136(12):2752–60.PubMedCrossRefGoogle Scholar
- 11.Nyitray AG, Carvalho Da Silva RJ, Baggio ML, Lu B, Smith D, Abrahamsen M, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis. 2011;203(1):49–57.PubMedPubMedCentralCrossRefGoogle Scholar
- 23.Ministry of Health Communications. British Columbia extends free HPV coverage to boys. 2017. http://news.gov.bc.ca/releases/2017HLTH0003-000027. Accessed 21 Aug 2017.
- 24.Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook 10th ed (2015 update). Canberra: Australian Government Department of Health; 2015.Google Scholar
- 28.The World Bank. Country and lending groups. 2016. http://data.worldbank.org/about/country-and-lending-groups#High_income. Accessed 8 Jan 2016.
- 29.The World Bank. GDP per capita (current US$). 2016. http://data.worldbank.org/indicator/NY.GDP.MKTP.KD.ZG. Accessed 8 Jan 2016.
- 32.Deshmukh AA, Chiao EY, Das P, Cantor SB. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. Vaccine. 2014;32(51):6941–7.PubMedPubMedCentralCrossRefGoogle Scholar
- 35.amfAR. Cervical cancer, human papillomavirus (HPV), and HPV vaccines in Southeast Asia: Key considerations for expanding vaccine coverage and improving population health. New York; The American Foundation for AIDS Research; 2016.Google Scholar
- 37.European Centre for Disease Prevention and Control. Introduction of HPV vaccines in European Union countries: an update. 2012. p. 1–40. http://ecdc.europa.eu/en/publications/publications/20120905_gui_hpv_vaccine_update.pdf. Accessed 8 Feb 2018.